The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Hemodynamic effects of quinapril, a novel angiotensin‐converting enzyme inhibitor
The hemodynamic effects of quinapril , a novel nonsulfhydryl‐containing angiotensin‐converting enzyme ( ACE ) inhibitor , were assessed in 10 patients with mild‐to‐moderate essential hypertension . Compared with placebo , quinapril ( 20 mg ) administered twice daily for 4 weeks significantly lowered blood pressure by decreasing total peripheral resistance without producing tachycardia , an increase in cardiac output , or a rise in plasma catecholamines . Quinapril significantly reduced renal , but not forearm , vascular resistance . Renal blood flow , glomerular filtration rate , and filtration fraction remained unchanged . Left ventricular wall stress was markedly reduced by quinapril , but during the relatively short treatment period , only a nonsignificant trend toward reduction in left ventricular mass was observed . These findings suggest that quinapril is an effective antihypertensive agent that lowers peripheral resistance without increasing cardiac output or disturbing autoregulation of renal hemodynamics
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .